Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2019-08-07 Investor Presentation
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Grant of further European patent
Investor Presentation Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Evgen Pharma PLC regarding the grant of a new European patent for their drug candidate SFX-01. It does not fit into specific categories like financial reports, dividends, or management changes. As it is a general regulatory announcement regarding corporate intellectual property developments, it falls under the RNS (Regulatory Filings) category.
2019-08-07 English
Research collaboration
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a research collaboration between Evgen Pharma and King's College London. Since it does not fit into specific categories like M&A, financial results, or board changes, and is a general corporate announcement provided via the RNS platform, it is classified as a Regulatory Filing (RNS).
2019-08-05 English
Grant of Options
Director's Dealing Classification · 100% confidence The document is an official notification regarding the grant of share options to Persons Discharging Managerial Responsibilities (PDMRs) at Evgen Pharma plc. It includes the specific 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' tables required by market regulations. This falls under the category of Director's Dealing (DIRS), as it reports share-based compensation/transactions involving company executives.
2019-07-25 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement from Evgen Pharma PLC regarding the 'Result of AGM'. It explicitly states that the Annual General Meeting was held and that all resolutions were duly passed. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the outcome of shareholder voting at the AGM.
2019-07-18 English
AGM Statement
AGM Information Classification · 98% confidence The document is an 'AGM Statement' released via RNS (Regulatory News Service) by Evgen Pharma PLC. It contains the Chairman's statement to be delivered at the Annual General Meeting, providing updates on clinical trials and company progress. While it mentions a presentation will be available on the website, the document itself serves as the official AGM statement/materials provided to shareholders. Therefore, it falls under the AGM-R category.
2019-07-18 English
Group of companies' accounts made up to 2019-03-31
Regulatory Filings
2019-07-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.